The Effects of Bioavailability-Enhanced Curcuminoids on Serum Paraoxonase-1 Activity in Patients with Metabolic Syndrome

Document Type : Original Article


1 Metabolic Syndrome Research Centre, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Department of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Biotechnology Research Centre and School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

4 Department of Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

5 Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

6 Cardiovascular Research Centre, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.


Introduction: Metabolic syndrome (MetS) is characterised by a clustering of metabolic cardiovascular disease (CVD) risk factors that include: central obesity, impaired glucose metabolism, dyslipidaemia (hypertriglyceridemia, increased low-density lipoprotein [LDL], decreased high-density lipoprotein [HDL]) and hypertension. Paraoxynase-1 (PON1) is a plasma HDL associated protein that inhibits the oxidation of other lipoproteins. There is some evidence of reduced enzyme activity in subjects with metabolic syndrome. Curcumin is a natural polyphenol, it has been reported that curcumin has beneficial effects on several metabolic syndrome associated parameters. The aim of this study was to evaluate the effect of phospholipid complex of curcumin as an antioxidant on the activity of this enzyme in subjects with metabolic syndrome.
Materials and Method: A double-blind randomised control study was undertaken in 80 patients with metabolic syndrome. Subjects in the intervention (n = 40) were given capsules of phospholipidated curcumin (1 g/day) for a period of 6 weeks. The control subjects (n = 40) received a placebo. Fasting blood samples of each person were obtained during the start and the end of the study. Paraoxonase activity was measured using a PON1 fluorescence Paraoxonase Assay Kit and Arylesterase activity was measured by photometeric method using a UV-Visible spectrophotometer.
Results: Serum paraoxonase enzyme activity did not change significantly between the curcumin treated group and the control group before the intervention (0.54 ± 0.18 U/µl versus 0.49 ± 0.14 U/µl; P > 0.05), nor did serum arylesteras activity change significantly between two study groups (152.67 [46.60 to 916.05] U/µl versus 129.77 [55.34 to 344.78] U/µl; P > 0.05). In addition, there was no significant difference in changes at baseline and after the intervention in serum PON1 activity between the curcumin treated group and the control group (-0.03±0.19 U/µl versus -0.04±0.18 U/µl; P > 0.05), nor was there a significant change in arylesteras activity (-12.36 [-88.83 to 110.24] U/µl versus -4.58 [-61.06 to 47.07] U/µl; P > 0.05).
Conclusion: Phospholipid fortified curcumin has no significant effect on serum PON1 activity. 


  1. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Jama. 2002 Dec 4;288(21):2709-16.
  2. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. Journal of the American College of Cardiology. 2010 Sep 28;56(14):1113-32.
  3. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinology and Metabolism Clinics. 2004 Jun 1;33(2):351-75.
  4. Maleki F, Sayehmiri F, Kiani F, Nasiri S. Metabolic syndrome prevalence in Iran: a systematic review and meta-analysis. Journal of Kermanshah University of Medical Sciences. 2014 Jul 30;18(4): 242-50.
  5. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Archives of internal medicine. 2004;164(10):1066-76.
  6. Mehrdad S, Hosseinpanah F, Azizi F. Metabolic syndrome prevalence in 3-9 years old children: Tehran Glucose and Lipid Study. Research in Medicine. 2006;30(4):337-46.
  7. Zabetian A, Hadaegh F, Azizi F. Prevalence of metabolic syndrome in Iranian adult population, concordance between the IDF with the ATPIII and the WHO definitions. Diabetes research and clinical practice. 2007;77(2):251-7.
  8. Jalali R, Vashaghani M, Dabaghmanesh M, Ranjbar Omrani G. Metabolic syndrome prevalence in adults of Akbar Abad Kovar, Fars Province, in 2008. Iranian Endocrinology and Metabolism Journal. 2009;11(4):405-14.
  9. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135-43.
  10. Assmann G, Gotto AM. HDL cholesterol and protective factors in atherosclerosis. Circulation. 2004;109(23 suppl 1):III-8-III-14.
  11. Lee JM, Choudhury RP. Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets. Heart. 2007;93(5):559-64.
  12. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arteriosclerosis, thrombosis, and vascular biology. 2001;21(4):481-8.
  13. Teiber JF, Draganov DI, La Du BN. Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochemical pharmacology. 2003;66(6):887-96.
  14. Hassett C, Richter RJ, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, et al. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry. 1991;30(42):10141-9.
  15. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochemical pharmacology. 2005;69(4):541-50.
  16. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radical Biology and Medicine. 1999;26(7):892-904.
  17. Martinelli N, Micaglio R, Consoli L, Guarini P, Grison E, Pizzolo F, et al. Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence the metabolic-syndrome-related risk of coronary artery disease. Experimental diabetes research. 2011;2012.
  18. Phuntuwate W, Suthisisang C, Koanantakul B, Mackness MI, Mackness B. Paraoxonase 1 status in the Thai population. Journal of human genetics. 2005;50(6):293-300.
  19. Boesch-Saadatmandi C, Egert S, Schrader C, Coumoul X, Barouki R, Muller M, et al. Effect of quercetin on paraoxonase 1 activity—studies in cultured cells, mice and humans. Journal of Physiology and Pharmacology. 2010;61(1):99.
  20. Visioli F, Davalos A. Polyphenols and cardiovascular disease: a critical summary of the evidence. Mini reviews in medicinal chemistry. 2011;11(14):1186-90.
  21. Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A. Curcuminoid Treatment for Knee Osteoarthritis: A Randomized Double‐Blind Placebo‐Controlled Trial. Phytotherapy Research. 2014;28(11):1625-31.
  22. Ashour M, Habib D, Hanna R, El-Dabaa M. Beneficial effects of curcumin and Ruta chalepensis on the antioxidant system and inflammation in hypercholesteromic rats. Aust J Basic Appl Sci. 2011;5:2562-7.
  23. Panahi Y, Saadat A, Beiraghdar F, Nouzari SMH, Jalalian HR, Sahebkar A. Antioxidant effects of bioavailability-enhanced curcuminoids in patients with solid tumors: a randomized double-blind placebo-controlled trial. Journal of Functional Foods. 2014;6:615-22.
  24. Seo KI, Choi MS, Jung UJ, Kim HJ, Yeo J, Jeon SM, et al. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Molecular nutrition & food research. 2008;52(9):995-1004.
  25. Mohammadi A, Sahebkar A, Iranshahi M, Amini M, Khojasteh R, Ghayour‐Mobarhan M, et al. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytotherapy Research. 2013;27(3):374-9.
  26. Shin SK, Ha TY, McGregor RA, Choi MS. Long‐term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Molecular nutrition & food research. 2011;55(12):1829-40.
  27. Sahebkar A. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors. 2013;39(2):197-208.
  28. Saberi-Karimian M, Parizadeh SM, Ghayour-Mobarhan M, Salahshooh MM, Dizaji BF, Safarian H, Javandoost A, Ferns GA, Sahebkar A, Ahmadinejad M. Evaluation of the effects of curcumin in patients with metabolic syndrome. Comparative Clinical Pathology. 2018 May;27(3):555-63.
  29. Schrader C, Schiborr C, Frank J, Rimbach G. Curcumin induces paraoxonase 1 in cultured hepatocytes in vitro but not in mouse liver in vivo. British Journal of Nutrition. 2011;105(02):167-70.
  30. Singh P, Ibrahim Rizvi S. Role of Curcumin in Modulating Plasma PON1 Arylesterase Activity and Susceptibility to LDL Oxidation in Oxidatively Challenged Wistar Rats. Letters in Drug Design & Discovery. 2015;12(4):319-23.
  31. Hasan S, Zingg J-M, Kwan P, Noble T, Smith D, Meydani M. Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice. Atherosclerosis. 2014;232(1):40-51.
  32. Mirzaei H, Shakeri A, Rashidi B, Jalili A, Banikazemi Z, Sahebkar A. Phytosomal curcumin: A review of pharmacokinetic, experimental and clinical studies. Biomedicine & Pharmacotherapy. 2017 Jan 1;85:102-12.
  33. Scapagnini G, Colombrita C, Amadio M, D’Agata, V, et al. 2006. Curcumin activates defensive genes and protects neurons against oxidative stress. Antioxidants & Redox Signaling 8:395-403.
  34. Mattson MP. 2008. Hormesis defined. Ageing Research Reviews 7: 1-7.
  35. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS letters. 1998;423(1):57-60.